Sarcopenia

Decoding Sarcopenia: Advances in Research and Management: Dive into the evolving landscape of sarcopenia research. From cutting-edge studies on its impact on cancer patients to innovative management strategies, gain insights into combating this muscle-wasting condition.

Sarcopenia in the Metropolitan Region of Chile: Cross-Sectional Findings from the Chilean National Health Survey 2016-2017.

AIM

To investigate sarcopenia in Chile, including its prevalence and association with sociodemographic and lifestyle factors.

METHODS

232 participants from the Metropolitan Region, representing 1,037,790 older adults, were included in this cross-sectional analysis. Sarcopenia was defined using the European Working Group on Sarcopenia...

🗓️ 2026-06-08
📰 Publication: Revista Medica De Chile
Read MoreSarcopenia in the Metropolitan Region of Chile: Cross-Sectional Findings from the Chilean National Health Survey 2016-2017.

Combined GLIM-defined malnutrition and sarcopenia and the risk of 2-year mortality in adults with heart failure: A FRAGILE-HF study post hoc analysis.

BACKGROUND

Malnutrition is common in older patients with heart failure and predicts poor outcomes. However, the prognostic value of assessing muscle function and fat stores alongside GLIM remains unclear. We therefore tested whether assessing handgrip strength and fat mass index alongside...

🗓️ 2026-06-03
📰 Publication: Journal Of Parenteral And Enteral Nutrition
Read MoreCombined GLIM-defined malnutrition and sarcopenia and the risk of 2-year mortality in adults with heart failure: A FRAGILE-HF study post hoc analysis.

Restoration of circadian rhythm as novel targets against sarcopenia.

Sarcopenia, characterized by the age-related decline in skeletal muscle mass, strength, and function, is associated with high healthcare costs and significant health risks, including falls, fractures, functional decline, and mortality. Despite its prevalence and extensive research, there are currently no...

🗓️ 2026-05-31
📰 Publication: Chinese Medical Journal
Read MoreRestoration of circadian rhythm as novel targets against sarcopenia.

Cluster Randomized Trial of Reablement Strategies Targeting Sarcopenia (ReStart-S) in Long-Term Care Settings.

BACKGROUND

Sarcopenia prevalence is high in long-term care settings (LTCS), yet existing guidelines often overlook this population. The Reablement Strategies targeting Sarcopenia (ReStart-S) program was developed to address this gap. This study evaluated its effects on muscle outcomes, physical performance, quality...

🗓️ 2026-05-31
📰 Publication: Journals Of Gerontology Series A-Biological Sciences And Medical Sciences
Read MoreCluster Randomized Trial of Reablement Strategies Targeting Sarcopenia (ReStart-S) in Long-Term Care Settings.

Artificial intelligence analysis of temporalis muscle thickness for monitoring sarcopenia and clinical outcomes in individuals with paediatric brain tumours: a retrospective cohort study.

BACKGROUND

People with and who have survived paediatric brain tumour (PBT) have a poor quality of life due to physiological frailty, a primary component of which is sarcopenia (ie, low lean muscle mass) and the associated condition, sarcopenic overweight. MRI-based temporalis...

🗓️ 2026-05-28
Read MoreArtificial intelligence analysis of temporalis muscle thickness for monitoring sarcopenia and clinical outcomes in individuals with paediatric brain tumours: a retrospective cohort study.

Sarcopenia in Diabetes: A proposal on integrating muscle assessment and nutritional intervention in people living with diabetes.

Sarcopenia is a progressive muscle disease characterized by loss of skeletal muscle mass and strength, commonly associated with ageing and chronic diseases. Type 2 diabetes mellitus (T2DM) accelerates its development through insulin resistance, chronic inflammation, oxidative stress, and hyperglycaemia. Sarcopenia...

🗓️ 2026-05-27
📰 Publication: Diabetes Research And Clinical Practice
Read MoreSarcopenia in Diabetes: A proposal on integrating muscle assessment and nutritional intervention in people living with diabetes.

Exploring the role of parathyroid hormone in sarcopenia: A review.

PURPOSE OF REVIEW

Sarcopenia is a progressive, multifactorial geriatric syndrome linked to increased risk of falls, fractures, disability, frailty, and all-cause mortality. The pathophysiology of this complex syndrome remains unclear. Emerging evidence suggests that chronically elevated parathyroid hormone (PTH) concentration may...

🗓️ 2026-05-27
Read MoreExploring the role of parathyroid hormone in sarcopenia: A review.

Circulating biomarkers in older adults with and without sarcopenia: a systematic review and meta-analysis.

BACKGROUND

Sarcopenia, the age-related loss of muscle mass and strength, poses a significant health and economic burden. This systematic review and meta-analysis evaluates circulating biomarkers (activin A, follistatin, growth differentiation factor (GDF-15), myostatin, growth hormone, insulin growth factor-1 (IGF-1), free and...

🗓️ 2026-05-27
📰 Publication: Journals Of Gerontology Series A-Biological Sciences And Medical Sciences
Read MoreCirculating biomarkers in older adults with and without sarcopenia: a systematic review and meta-analysis.

The Gut-Muscle Axis in Sarcopenia: Mechanisms, Evidence Gaps and Translational Challenges.

Sarcopenia is an age-related skeletal muscle disorder characterized by reduced muscle mass, strength, and physical performance, as well as increased risk of disability, hospitalization, and mortality. Emerging evidence suggests that gut microbiota alterations may contribute to muscle decline via a...

🗓️ 2026-05-27
Read MoreThe Gut-Muscle Axis in Sarcopenia: Mechanisms, Evidence Gaps and Translational Challenges.

Ginsenoside Ro ameliorates d-galactose-induced sarcopenia by modulating oxidative stress, inflammation, and gut microbiota in mice.

BACKGROUND

Sarcopenia is an age-related disorder primarily characterized by progressive muscle degeneration, and effective therapeutic interventions for this condition remain limited. Ginsenoside Ro (GRo) exhibits antioxidant and anti-inflammatory effects. However, the impact of GRo on skeletal muscle aging, myoblast differentiation, and...

🗓️ 2026-05-22
📰 Publication: Phytomedicine
Read MoreGinsenoside Ro ameliorates d-galactose-induced sarcopenia by modulating oxidative stress, inflammation, and gut microbiota in mice.

Body Composition Changes in Patients on GLP-1 Receptor Agonists Undergoing an Intensive Cardiac Rehabilitation Program.

BACKGROUND

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes and obesity and produce significant weight loss. However, concerns have emerged about potential loss of skeletal muscle mass (SMM) with pharmacologic weight reduction, particularly in older adults...

🗓️ 2026-05-21
📰 Publication: European Journal Of Preventive Cardiology
Read MoreBody Composition Changes in Patients on GLP-1 Receptor Agonists Undergoing an Intensive Cardiac Rehabilitation Program.

Why Osteosarcopenia Matters: Clinical and Investigative Implications.

BACKGROUND

Osteosarcopenia, the combination of osteoporosis and sarcopenia, is a geriatric syndrome linked to functional decline, falls, and fragility fractures. The interaction among bone, muscle, and their shared pathophysiology is driven by mechanical, metabolic, and hormonal factors. With global population aging...

🗓️ 2026-05-15
📰 Publication: European Journal Of Clinical Investigation
Read MoreWhy Osteosarcopenia Matters: Clinical and Investigative Implications.

A narrative review of sarcopenia in patients with cardiovascular kidney metabolic syndrome: Another brick in the wall?

Cardiovascular-kidney-metabolic syndrome (CKMS) is a recently launched by American Heart Association to express the importance of interplay among metabolic risk factors, chronic kidney disease, and the cardiovascular system which has profound impacts on morbidity and mortality. The common pathologic processes...

🗓️ 2026-05-13
📰 Publication: Clinical Nutrition
Read MoreA narrative review of sarcopenia in patients with cardiovascular kidney metabolic syndrome: Another brick in the wall?

Discovery of a Potent Antisarcopenia Drug Molecular Scaffold Derived from Ligusticum chuanxiong and Its Photochemical Synthesis.

Sarcopenia is a growing public health crisis with an unmet need for effective pharmacotherapies. Ligusticum chuanxiong (L. chuanxiong), commonly known as Chuanxiong in China, is a medicinal plant widely utilized for conditions involving muscle wasting and weakness. Herein, we report...

🗓️ 2026-05-11
📰 Publication: Journal Of The American Chemical Society
Read MoreDiscovery of a Potent Antisarcopenia Drug Molecular Scaffold Derived from Ligusticum chuanxiong and Its Photochemical Synthesis.

The diagnostic accuracy of blood biomarkers for sarcopenia, sarcopenic obesity, and osteosarcopenia: a meta-analysis.

BACKGROUND AND AIMS

Sarcopenia is the accelerated loss of skeletal muscle mass and function associated with ageing. Sarcopenia screening consists of body composition imaging and physical function tests; however, these tests can be burdensome and inconsistent. This review aimed to synthesise...

🗓️ 2026-05-11
📰 Publication: Archives Of Gerontology And Geriatrics
Read MoreThe diagnostic accuracy of blood biomarkers for sarcopenia, sarcopenic obesity, and osteosarcopenia: a meta-analysis.

SARCOPENIA DEFINITION

Sarcopenia is a condition which focuses on muscle loss. Loss of muscle mass and function, especially muscle strength and gait speed, associated with aging occurs in sarcopenia. Sarcopenia, cachexia, and malnutrition are considered as the main causes of muscle wasting and affect millions of elderly people and patients. Moreover, muscle atrophy can develop independently from diseases and age through disuse of the muscles. For a better classification and common language in medical science for ‘muscle wasting disease’ there is a proposal to combine the concepts of muscle wasting, sarcopenia, frailty, and cachexia by disease aetiology and disease progression. Patients with muscle atrophy show decreased muscle strength and therefore reduced quality of life, which is caused by a lower activity and increased exercise intolerance.

Despite a large number of studies, the understanding of the development of muscle wasting and the involved pathways remains very limited and more research is needed. Although many researchers and pharmaceutical companies have tried to find therapies for muscle atrophy, including cachexia and sarcopenia, no solution has been established until now.

REFERENCES

Rosenberg IH. Sarcopenia: origins and clinical relevance. Clin Geriatr Med 2011;27:337–339.

Anker SD, Coats AJ, Morley JE, Rosano G, Bernabei R, von Haehling S, Kalantar-Zadeh K. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014;5:1–3

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!